Get the Stockscreener App
0.4958
2.40%
-0.0122
After Hours:
.49
-0.0058
-1.17%
Immunoprecise Antibodies Ltd stock is traded at $0.4958, with a volume of 757.59K.
It is down -2.40% in the last 24 hours and down -7.33% over the past month.
ImmunoPrecise Antibodies Ltd is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges.
See More
Previous Close:
$0.508
Open:
$0.51
24h Volume:
757.59K
Relative Volume:
0.13
Market Cap:
$23.61M
Revenue:
$16.77M
Net Income/Loss:
$-11.87M
P/E Ratio:
-1.0456
EPS:
-0.4742
Net Cash Flow:
$-5.90M
1W Performance:
+6.58%
1M Performance:
-7.33%
6M Performance:
-37.24%
1Y Performance:
-77.57%
1-Day Range:
$0.4818
$0.534
1-Week Range:
$0.4279
$0.534
52-Week Range:
$0.3248
$2.4299
Immunoprecise Antibodies Ltd Stock (IPA) Company Profile
Name
Immunoprecise Antibodies Ltd
Sector
Industry
Phone
-
Address
-
Compare IPA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IPA
Immunoprecise Antibodies Ltd
|
0.4958 | 23.61M | 16.77M | -11.87M | -5.90M | -0.4742 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.23 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immunoprecise Antibodies Ltd Stock (IPA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-22 | Initiated | H.C. Wainwright | Buy |
| Oct-25-21 | Initiated | The Benchmark Company | Buy |
Immunoprecise Antibodies Ltd Stock (IPA) Latest News
ImmunoPrecise Antibodies Ltd (IPA) Shares Up Despite Recent Market Volatility - The News Heater
Check Out ImmunoPrecise Antibodies Ltd (IPA)’s Trade Data Rather Than the Analysts’ Views - SETE News
ImmunoPrecise Antibodies Ltd (IPA) presents a great opportunity, but the stock is slightly overvalued - US Post News
ImmunoPrecise Antibodies Boosts Financial Position Through Successful Capital Initiatives - TipRanks
ImmunoPrecise Antibodies (OTCMKTS:IPATF) Shares Down 3.9% – Here’s Why - Defense World
ImmunoPrecise Antibodies Ltd. (IPA) Unveils AI-Developed GLP-1 Therapies for Type 2 Diabetes and Obesity, Pioneering New Frontiers in Biotech Innovation - Insider Monkey
ImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville Debenture - The Globe and Mail
ImmunoPrecise Antibodies Strengthens Financial Position with Strategic Capital Initiatives - TipRanks
Benchmark maintains Buy on Immunoprecise stock, target at $3.00 - MSN
Benchmark maintains Buy on Immunoprecise stock, target at $3.00 By Investing.com - Investing.com Canada
Immunoprecise uses AI to develop new class of GLP-1 therapies - BioWorld Online
ImmunoPrecise Antibodies develops new class of GLP-1 therapies through AI - Yahoo Finance
Stock Traders Buy High Volume of ImmunoPrecise Antibodies Call Options (NASDAQ:IPA) - Defense World
What's Going On With ImmunoPrecise Antibodies Stock Wednesday? - Benzinga
S&P 500 Growth (IGX) QuotePress Release - The Globe and Mail
TSX Renewable and Clean Tech Index (TXCT) QuotePress Release - The Globe and Mail
TSX 60 Index (TXSX) QuotePress Release - The Globe and Mail
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
TSX Global Mining Index (TXGM) QuotePress Release - The Globe and Mail
ImmunoPrecise Antibodies Leverages AI for Next-Gen Diabetes Treatment - TipRanks
IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment - Business Wire
ImmunoPrecise Antibodies Ltd. (IPA) Launches AI-Powered Drug Discovery Pipeline, Revolutionizing Therapeutic Development with LENSai™ Platform - Insider Monkey
10 Trending AI Stocks on Latest News and Ratings - Insider Monkey
ImmunoPrecise launches AI-driven drug discovery pipeline - Investing.com India
ImmunoPrecise launches AI-driven drug discovery pipeline By Investing.com - Investing.com Canada
ImmunoPrecise Antibodies Launches AI-Powered Drug Discovery Platform - TipRanks
ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation - Business Wire
Even With A 30% Surge, Cautious Investors Are Not Rewarding ImmunoPrecise Antibodies Ltd.'s (NASDAQ:IPA) Performance Completely - Simply Wall St
ImmunoPrecise Antibodies (NASDAQ:IPA) Stock Price Up 15.5% – What’s Next? - Defense World
ImmunoPrecise Antibodies Announces CFO Resignation - TipRanks
ImmunoPrecise Antibodies finance chief to step down - MSN
ImmunoPrecise Antibodies announces resignation of CFO - Yahoo Finance
ImmunoPrecise Antibodies Ltd. Announces the Resignation of Kristin Taylor as Chief Financial Officer, Effective January 16, 2025 - Marketscreener.com
ImmunoPrecise Antibodies CFO Resignation and Succession - TipRanks
ImmunoPrecise Antibodies CFO Kristin Taylor Announces Resignation, Will Transition Through January 2025 - StockTitan
IPA Announces Resignation of Chief Financial Officer - Business Wire
ImmunoPrecise Antibodies (IPA) Demonstrates Strong Market Confidence with Insider Share Purchases - The Globe and Mail
ImmunoPrecise Antibodies to Present at Microcap Conference 2025: AI-Driven Biotech Showcase - StockTitan
ImmunoPrecise Antibodies to Showcase at Microcap Conference - TipRanks
IPA to Present at The Microcap Conference 2025 - Business Wire
HC Wainwright Has Optimistic Outlook of IPA Q3 Earnings - Defense World
Research Analysts Set Expectations for IPA FY2028 Earnings - Defense World
Immunoprecise Antibodies Ltd Stock (IPA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):